<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04835779</url>
  </required_header>
  <id_info>
    <org_study_id>18-018</org_study_id>
    <nct_id>NCT04835779</nct_id>
  </id_info>
  <brief_title>Biometric and Biological Data for Diagnosis and Therapy of Pain Patients</brief_title>
  <acronym>Bio2Treat</acronym>
  <official_title>Biometric and Biological Data for Diagnosis and Therapy of Pain Patients German: Biometrische Und Biologische Daten für Die Diagnose Und Therapie Bei Schmerzpatienten</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grünenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to meet the challenge of an unambiguous diagnosis and effective therapy of SFN or&#xD;
      the prognosis of susceptibility to the development of SFN, this project aims to create a data&#xD;
      basis on which software will be developed during the project. This software should later be&#xD;
      able to combine (integrate) quantifiable biometric data collected from the patient (both&#xD;
      objectively measured and patient reported parameters) with the results of biological analyses&#xD;
      of the patient's own nerve cells from stem cells. We expect that the patient-specific&#xD;
      combination and correlation of biometric and biological data can lead to a significant&#xD;
      improvement in the diagnosis, prognosis and therapy of chronic pain. The initial data&#xD;
      collection required for the development of such a software (Bio2Integrate) will be carried&#xD;
      out in three different project parts: Bio2Watch, Bio2Patient and Bio2Cell&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bio2Watch: In this clinical project part biometric patient data of 24 SFN patients, 3 cancer&#xD;
      patients and 21 subjects (control group) will be collected for a period of one year using a&#xD;
      PainWatch. The term PainWatch includes an Apple Watch 5 with iPhone 8 and installed app for&#xD;
      pain recording. With the aid of the PainWatch, the personal pain sensation in everyday life&#xD;
      is documented and personal data such as the pulse rate and the daily number of steps, as well&#xD;
      as environmental data, such as the prevailing air pressure, humidity and temperature are&#xD;
      recorded. The aim is to use these data as a basis for initial indications of pain-inducing&#xD;
      stimuli or combinations of stimuli.&#xD;
&#xD;
      Bio2Patient: In this clinical project part clinically quantifiable tests are carried out,&#xD;
      such as quantitative sensory testing (QST), which examines subjective thermal and mechanical&#xD;
      sensory perception and pain thresholds. The goal is to determine a specific pain phenotype.&#xD;
      In addition, pain evoked potentials (PREPs) are performed to draw conclusions about the&#xD;
      function of thin nerve fibers (pain fibers), including projection to the brain. Supplementary&#xD;
      SF-36 pain questionnaires are completed to assess the quality of life.&#xD;
&#xD;
      Bio2Cell: In the cell-based project part induced pluripotent stem cells (iPS cells) are&#xD;
      produced from blood cells of SFN patients, cancer patients and volunteers. These cells will&#xD;
      be differentiated into sensory neurons that are relevant in pain processing, so-called&#xD;
      nociceptors. Since these nociceptors are derived from the individual patient, they carry the&#xD;
      individual genetic characteristics of the patient. These neurons are then analyzed by&#xD;
      multi-electrode arrays (MEA). With this method environmental influences such as temperature&#xD;
      and air pressure or drugs on the pathophysiology of the patient's are investigated. The main&#xD;
      goal is to simulate the conditions, which lead to pain sensation in the context of Bio2Watch&#xD;
      and Bio2Patient.&#xD;
&#xD;
      Bio2Integrate: The results from Bio2Watch, Bio2Patient and Bio2Cell will then flow into the&#xD;
      software to be developed during the project. Thus, in addition to the identification of&#xD;
      stimuli that stimulate pain as well as a genetic correlation to certain markers will be&#xD;
      possible. In addition, the targeted modification of the cellular properties of the patient's&#xD;
      own sensory neurons through the application of the chemotherapeutic agent can be&#xD;
      investigated. To this end, measurements will be made on the cells before and after the&#xD;
      application of the substance and compare them with each other. This is the basis for&#xD;
      components of the &quot;machine learning &quot; of the Bio2Integrate software.The results of the&#xD;
      clinical subprojects are thus an essential component of Bio2Integrate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2020</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PainWatch Data</measure>
    <time_frame>12 months</time_frame>
    <description>pulse rate (/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PainWatch Data</measure>
    <time_frame>12 months</time_frame>
    <description>number of steps</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PainWatch Data</measure>
    <time_frame>12 months</time_frame>
    <description>pain perception via App (Questionnaire, pain scale 1-10)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weather Data tracked according to GPS Location</measure>
    <time_frame>12 months</time_frame>
    <description>Temperature (°C)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weather Data tracked according to GPS Location</measure>
    <time_frame>12 months</time_frame>
    <description>Air pressure (Pa)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weather Data tracked according to GPS Location</measure>
    <time_frame>12 months</time_frame>
    <description>Humidity (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Test result QST</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement exclusively above the back of the foot that is clinically more severely affected by the SFN, in a balanced row alternately above the right or left foot; one back of the foot as test site per subject</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Test result PREP (over the same back of the foot as in QST measurement)</measure>
    <time_frame>12 months</time_frame>
    <description>P1 Latency (ms)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Test result PREP (over the same back of the foot as in QST measurement)</measure>
    <time_frame>12 months</time_frame>
    <description>Peak-to-Peak (microV)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Test result PREP (over the same back of the foot as in QST measurement)</measure>
    <time_frame>12 months</time_frame>
    <description>Current intensity (mA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Result SF 36 Questionnaire</measure>
    <time_frame>12months</time_frame>
    <description>Result SF 36 Questionnaire (different scales per question)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Results of the Multi-Electrode Array investigations</measure>
    <time_frame>12 months</time_frame>
    <description>Spontaneous activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Results of the Multi-Electrode Array investigations</measure>
    <time_frame>12 months</time_frame>
    <description>Synchronicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Results of the Multi-Electrode Array investigations</measure>
    <time_frame>12 months</time_frame>
    <description>Field potential properties</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Results of the Multi-Electrode Array investigations</measure>
    <time_frame>12 months</time_frame>
    <description>Activity inducing stimuli</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficiency of reprogramming and differentiation of iPS cells</measure>
    <time_frame>12 months</time_frame>
    <description>Success of differentiation will be measured by flow cytometry at around d10 of differentiation. The percentage of p75 (CD271)-expressing cells will be meassured. The differentiation is defined as successful if more than 30% of cells express p75. Only those differentiations will be used for MEA-Recordings.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Small Fiber Neuropathy</condition>
  <arm_group>
    <arm_group_label>SFN Patients</arm_group_label>
    <description>Patients with diagnosed Small Fibre Neuropathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients undergoing chemotherapy</arm_group_label>
    <description>Patients undergoing chemotherapy and are expected to develop SFN as a result</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteer</arm_group_label>
    <description>Healthy test person</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        SFN Patients (Group A): Patients diagnosed with Small Fibre Neuropathia Healthy Volunteers&#xD;
        (Group B): Healthy grown-up Volunteers Patients undergoing chemotherapy (Group C): Patients&#xD;
        with imminent initiation of neurotoxic chemotherapy in cancer with solid tumors (preferably&#xD;
        of the gastrointestinal tract) with the side-effect of SFN development. There are no plans&#xD;
        for follow-up recruitment in case no neuropathy develops after chemo.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group A: Criteria 1-5 Group B: Criteria 2-5 Group C: Criteria 2-6&#xD;
&#xD;
          1. Small fiber neuropathy (after clinical examination or QST or skin biopsy findings)&#xD;
&#xD;
          2. Legal age&#xD;
&#xD;
          3. Written declaration of consent&#xD;
&#xD;
          4. Persons who are legally competent and mentally capable of following the instructions&#xD;
             of the staff&#xD;
&#xD;
          5. Sufficient affinity for independent handling of the technology used (PainWatch incl.&#xD;
             the corresponding apps) for daily digital pain recording&#xD;
&#xD;
          6. Imminent initiation of neurotoxic chemotherapy in cancer with solid tumors (preferably&#xD;
             of the gastrointestinal tract) There are no plans for follow-up recruitment in case no&#xD;
             neuropathy develops after chemo.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For all Groups:&#xD;
&#xD;
          1. Persons who are accommodated in an institution by order of the authorities or courts&#xD;
&#xD;
          2. Persons who are in a dependent or employment relationship with the auditor&#xD;
&#xD;
          3. For test persons: Exclusion, if they carry a known pain-relevant genetic&#xD;
             variant/mutation or suffer from a chronic pain disorder analogous to migraine or&#xD;
             chronic back pain.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Rolke, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Aachen, AöR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roman Rolke, Prof. Dr.</last_name>
    <phone>+49 241 8080880</phone>
    <email>rrolke@ukaachen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lampert Angelika, Prof. Dr.</last_name>
    <phone>+49 241 80 88811</phone>
    <email>alampert@ukaachen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen, Klinik für Palliativmedizin</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Rolke, Prof.Dr.med</last_name>
      <phone>+49-241-8080880</phone>
      <email>rrolke@ukaachen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Lacomis D. Small-fiber neuropathy. Muscle Nerve. 2002 Aug;26(2):173-88. Review.</citation>
    <PMID>12210380</PMID>
  </reference>
  <reference>
    <citation>Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, Broglio L, Granieri E, Lauria G. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008 Jul;131(Pt 7):1912-25. doi: 10.1093/brain/awn093. Epub 2008 Jun 4.</citation>
    <PMID>18524793</PMID>
  </reference>
  <reference>
    <citation>Rolke R, Rolke S, Hiddemann S, Mücke M, Cuhls H, Radbruch L, Elsner F, Peuckmann-Post V. [Update palliative pain therapy]. Internist (Berl). 2016 Oct;57(10):959-970. Review. German.</citation>
    <PMID>27631529</PMID>
  </reference>
  <reference>
    <citation>Dworkin RH, O'Connor AB, Kent J, Mackey SC, Raja SN, Stacey BR, Levy RM, Backonja M, Baron R, Harke H, Loeser JD, Treede RD, Turk DC, Wells CD. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain. 2013 Nov;154(11):2249-2261. doi: 10.1016/j.pain.2013.06.004. Epub 2013 Jun 6. Review.</citation>
    <PMID>23748119</PMID>
  </reference>
  <reference>
    <citation>Coluzzi F, Rolke R, Mercadante S. Pain Management in Patients with Multiple Myeloma: An Update. Cancers (Basel). 2019 Dec 17;11(12). pii: E2037. doi: 10.3390/cancers11122037. Review.</citation>
    <PMID>31861097</PMID>
  </reference>
  <reference>
    <citation>Meents JE, Bressan E, Sontag S, Foerster A, Hautvast P, Rösseler C, Hampl M, Schüler H, Goetzke R, Le TKC, Kleggetveit IP, Le Cann K, Kerth C, Rush AM, Rogers M, Kohl Z, Schmelz M, Wagner W, Jørum E, Namer B, Winner B, Zenke M, Lampert A. The role of Nav1.7 in human nociceptors: insights from human induced pluripotent stem cell-derived sensory neurons of erythromelalgia patients. Pain. 2019 Jun;160(6):1327-1341. doi: 10.1097/j.pain.0000000000001511.</citation>
    <PMID>30720580</PMID>
  </reference>
  <reference>
    <citation>Mücke M, Cuhls H, Radbruch L, Baron R, Maier C, Tölle T, Treede RD, Rolke R. [Quantitative sensory testing]. Schmerz. 2014 Dec;28(6):635-46; quiz 647-8. doi: 10.1007/s00482-014-1485-4. German.</citation>
    <PMID>25403802</PMID>
  </reference>
  <reference>
    <citation>Lefaucheur JP, Ahdab R, Ayache SS, Lefaucheur-Ménard I, Rouie D, Tebbal D, Neves DO, Ciampi de Andrade D. Pain-related evoked potentials: a comparative study between electrical stimulation using a concentric planar electrode and laser stimulation using a CO2 laser. Neurophysiol Clin. 2012 Jun;42(4):199-206. doi: 10.1016/j.neucli.2011.12.003. Epub 2012 Jan 20.</citation>
    <PMID>22632868</PMID>
  </reference>
  <reference>
    <citation>Hansen N, Obermann M, Uçeyler N, Zeller D, Mueller D, Yoon MS, Reiners K, Sommer C, Katsarava Z. [Clinical application of pain-related evoked potentials]. Schmerz. 2012 Feb;26(1):8-15. doi: 10.1007/s00482-011-1117-1. Review. German.</citation>
    <PMID>22134376</PMID>
  </reference>
  <reference>
    <citation>Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 1993 May 29;306(6890):1437-40.</citation>
    <PMID>8518639</PMID>
  </reference>
  <reference>
    <citation>Lee J, Mawla I, Kim J, Loggia ML, Ortiz A, Jung C, Chan ST, Gerber J, Schmithorst VJ, Edwards RR, Wasan AD, Berna C, Kong J, Kaptchuk TJ, Gollub RL, Rosen BR, Napadow V. Machine learning-based prediction of clinical pain using multimodal neuroimaging and autonomic metrics. Pain. 2019 Mar;160(3):550-560. doi: 10.1097/j.pain.0000000000001417.</citation>
    <PMID>30540621</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RWTH Aachen University</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Roman Rolke</investigator_full_name>
    <investigator_title>Direktor Klinik für Palliativmedizin</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>SFN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Fiber Neuropathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

